UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061773 |
|---|---|
| Receipt number | R000070685 |
| Scientific Title | Effect of Daily Ingestion of Difructose Anhydride III (DFA III) on Visceral Fat : A Preliminary Study |
| Date of disclosure of the study information | 2026/06/03 |
| Last modified on | 2026/06/02 12:06:23 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of Daily Ingestion of Difructose Anhydride III (DFA III) on Visceral Fat : A Preliminary Study
Acronym
Effect of Daily Ingestion of Difructose Anhydride III (DFA III) on Visceral Fat : A Preliminary Study
Scientific Title
Effect of Daily Ingestion of Difructose Anhydride III (DFA III) on Visceral Fat : A Preliminary Study
Scientific Title:Acronym
Effect of Daily Ingestion of Difructose Anhydride III (DFA III) on Visceral Fat : A Preliminary Study
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effects and the effective dose of 16-week DFA III ingestion on visceral fat in a randomized, double-blind, placebo-controlled, parallel-group study.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Visceral fat area at 16 weeks after ingestion.
Key secondary outcomes
Total fat area, subcutaneous fat area, body composition, blood glucose, gut microbiota, short-chain fatty acids in feces, blood metabolome analysis.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
NO
Institution consideration
Blocking
YES
Concealment
No need to know
Intervention
No. of arms
3
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Daily ingestion two packets (2.5 g per packet) of test food 1 for 16 weeks.
Interventions/Control_2
Daily ingestion two packets (2.5 g per packet) of test food 2 for 16 weeks.
Interventions/Control_3
Daily ingestion two packets (2.5 g per packet) of placebo food for 16 weeks.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1. Those who agree to participate in this study with a written informed consent.
2. Those with BMI is >=23 kg/m2 and <30 kg/m2 at the time of screening.
Key exclusion criteria
1. Subjects who are under physician's advice, treatment, and/or medication for obese, diabetes, and/or dyslipidemia.
2. Subjects with implantable electronic medical devices.
3. Subjects who have metal implants at the CT scan site.
4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, endocrine diseases and/or affected with infectious diseases requiring reports to the authorities.
5. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
7. Subjects with severe anemia.
8. Pre- or post-menopausal women complaining of obvious physical changes.
9. Subjects who are at risk of having allergic reactions to drugs or foods.
10. Subjects who regularly take medicine, functional foods, and/or supplements which would affect obese and/or intestinal environment.
11. Subjects with oligosaccharide intolerance.
12. Subjects who changes in body weight of 10% or more within 12 wks prior to the screening.
13. Subjects whose lifestyle is planned to change during the study.
14. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
15. Subjects who donated either 400 ml whole blood within 16 wks (women), 12 wks(men), 200 ml whole blood within 4 wks (men and women), or blood components within 2 wks (men and women), prior to the screening.
16. Pregnant or lactating women or those planning to become pregnant.
17. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study.
18. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Target sample size
45
Research contact person
Name of lead principal investigator
| 1st name | Naoyuki |
| Middle name | |
| Last name | HONMA |
Organization
Hokkaido Information University
Division name
Department of Medical Management and Informatics
Zip code
069-8585
Address
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL
011-385-4430
hisc-acad.res@s.do-johodai.ac.jp
Public contact
Name of contact person
| 1st name | Naoyuki |
| Middle name | |
| Last name | HONMA |
Organization
Hokkaido Information University
Division name
Health Information Science Center
Zip code
069-8585
Address
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL
011-385-4430
Homepage URL
hisc-acad.res@s.do-johodai.ac.jp
Sponsor or person
Institute
Hokkaido Information University
Institute
Department
Personal name
Funding Source
Organization
Nippon Beet Suger Manufacturing Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The ethics committee of Hokkaido Information University
Address
59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
Tel
011-385-4411
soumu@do-johodai.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道情報大学 保健センター（北海道）
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 06 | Month | 03 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 05 | Month | 28 | Day |
Date of IRB
| 2026 | Year | 05 | Month | 28 | Day |
Anticipated trial start date
| 2026 | Year | 06 | Month | 09 | Day |
Last follow-up date
| 2026 | Year | 12 | Month | 26 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 06 | Month | 02 | Day |
Last modified on
| 2026 | Year | 06 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070685
